medwireNews: Patients with unresectable stage III EGFR-mutated non-small-cell lung cancer (NSCLC) could benefit from the use of osimertinib after chemoradiotherapy, suggest phase 3 trial data.
03-06-2024 | NSCLC | News
03-06-2024 | NSCLC | News
medwireNews: Patients with unresectable stage III EGFR-mutated non-small-cell lung cancer (NSCLC) could benefit from the use of osimertinib after chemoradiotherapy, suggest phase 3 trial data.